Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Other Accumulated Expenses (2023 - 2025)

Cytosorbents' Other Accumulated Expenses history spans 3 years, with the latest figure at $965000.0 for Q2 2025.

  • Quarterly results put Other Accumulated Expenses at $965000.0 for Q2 2025, changed N/A from a year ago — trailing twelve months through Jun 2025 was $965000.0 (changed N/A YoY), and the annual figure for FY2024 was $812000.0, down 18.11%.
  • Other Accumulated Expenses for Q2 2025 was $965000.0 at Cytosorbents, up from $796925.0 in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $991545.0 in Q4 2023 to a low of $796925.0 in Q1 2025.
  • The 3-year median for Other Accumulated Expenses is $888500.0 (2024), against an average of $891367.5.
  • Peak annual rise in Other Accumulated Expenses hit 18.11% in 2024, while the deepest fall reached 18.11% in 2024.
  • Year by year, Other Accumulated Expenses stood at $991545.0 in 2023, then fell by 18.11% to $812000.0 in 2024, then rose by 18.84% to $965000.0 in 2025.
  • According to Business Quant data, Other Accumulated Expenses over the past three periods came in at $965000.0, $796925.0, and $812000.0 for Q2 2025, Q1 2025, and Q4 2024 respectively.